Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, argenx SE's enterprise value is $47,551 Mil.
argenx SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,751 Mil. Therefore, argenx SE's EV-to-EBITDA for today is 27.15.
The historical rank and industry rank for argenx SE's EV-to-EBITDA or its related term are showing as below:
ARGX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -693.5 Med: -34.52 Max: 477.34
Current: 27.36
During the past 13 years, the highest EV-to-EBITDA of argenx SE was 477.34. The lowest was -693.50. And the median was -34.52.
ARGX's EV-to-EBITDA is ranked worse than 69.4% of 402
companies
in the Biotechnology industry
Industry Median: 13.825
vs ARGX: 27.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
argenx SE's share price for today is $851.56.
argenx SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for argenx SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where argenx SE's EV-to-EBITDA falls into.
argenx SE's current Enterprise Value is $47,551 Mil.
argenx SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,751 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a EV-to-EBITDA of 27.15 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on argenx SE. According to the industry distribution chart, argenx SE ranks #279 out of 402 companies in the Biotechnology industry, placing it in the top 69.4%.
Is argenx SE's EV-to-EBITDA too high?
argenx SE's current EV-to-EBITDA is 27.15. The Biotechnology industry median EV-to-EBITDA is 13.83. argenx SE's value of 27.15 is 96.4% above this industry median. Based on the distribution chart, argenx SE ranks #279 out of 402 companies in the Biotechnology industry, which is below the industry midpoint. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #279 out of 402 companies for EV-to-EBITDA. This places argenx SE in the lower half of its industry. The industry median EV-to-EBITDA is 13.83. argenx SE's value of 27.15 is 96.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.83, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current EV-to-EBITDA of 27.15 is 96.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on argenx SE. For the Biotechnology industry, the median EV-to-EBITDA is 13.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current EV-to-EBITDA is 27.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,443.12, compared to a current price of $851.56 — trading 41% below its estimated fair value. The current EV-to-EBITDA is 27.15 and 96.4% above the Biotechnology industry median of 13.83. argenx SE's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For argenx SE (ARGX), the current EV-to-EBITDA is 27.15 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $851.56 is trading 41% below its estimated GF Value™ of $1,443.12.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
EV-to-EBITDA: 27.15
GF Value™: $1,443.12 vs. price of $851.56 (41% below fair value)
Industry Position: 96.4% above the Biotechnology median (#279 of 402)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for ARGX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
